Abaxis Misses on the Top and Bottom Lines
Abaxis (NAS: ABAX) reported earnings on Jan. 26. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended Dec. 31 (Q3), Abaxis missed on revenues and missed expectations on earnings per share.
Compared to the prior-year quarter, revenue grew and earnings per share shrank significantly.
Margins shrank across the board.
Abaxis tallied revenue of $37.9 million. The nine analysts polled by S&P Capital IQ foresaw revenue of $40.7 million. Sales were 5.4% higher than the prior-year quarter's $35.9 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions.
EPS came in at $0.13. The nine earnings estimates compiled by S&P Capital IQ predicted $0.16 per share. GAAP EPS of $0.13 for Q3 were 24% lower than the prior-year quarter's $0.17 per share.
Source: S&P Capital IQ. Quarterly periods. Figures may be non-GAAP to maintain comparability with estimates.
For the quarter, gross margin was 54.1%, 110 basis points worse than the prior-year quarter. Operating margin was 12.3%, 390 basis points worse than the prior-year quarter. Net margin was 7.5%, 320 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $42.7 million. On the bottom line, the average EPS estimate is $0.19.
Next year's average estimate for revenue is $159.1 million. The average EPS estimate is $0.59.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 157 members out of 172 rating the stock outperform, and 15 members rating it underperform. Among 48 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 46 give Abaxis a green thumbs-up, and two give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Abaxis is outperform, with an average price target of $32.
The health-care investing landscape is littered with also-rans and a few major winners. Is Abaxis the right stock for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company Fool co-founder David Gardner believes will be a phenomenal success over the next few years. Click here for instant access to this free report.
- Add Abaxis to My Watchlist.
At the time this article was published Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.